Leishmaniasis: A study model for host-parasite interactions; implications for human disease;Les leishmanioses: Un modele d'etude des interactions hote-parasite; implications pour la maladie humaine

Annales de l'Institut Pasteur/Actualites

Volumn 10, Issue 1, 1999, Pages 67-80

  Louzir, Hechmi ^a   Dellagi, Koussay ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; HOST PARASITE INTERACTION; IMMUNOPATHOLOGY; LEISHMANIASIS; MOUSE; NONHUMAN; REVIEW;

ANIMALIA;

EID: 0032733368     PISSN: 09244204     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-4204(99)80023-7     Document Type: Article

References (137)

1. Acha-Orbea H., Shakhov A.N., Scarpellino M. et al., Clonal deletion of Vb14-bearing T cells in mice trangenic for mammary tumor virus, Nature 350 (1991) 207-211.
2. Alexander J. Russel D.G., The interaction of Leishmania species with macrophages, Adv. Parasitol. 31 (1992) 175-253.
3. Alvar J., Balsquez J., Najera R., Association of visceral leishmaniasis and human immunodeficiency virus infection, J. Infect. Dis. 160 (1989) 560-561.
4. Alvarado R., Enk C., Jaber K., Schur L., Frankenburg S., Delayed-type hypersensitivity and lymphocyte proliferation in response to Leishmania major infection in group of children in Jericho, Trans. Roy. Soc. Trop. Med. Hyg. 83 (1989) 189-192.
5. Andrade T.M., Carvalho E.M., Rocha H., Bacterial infections in patients with visceral leishmaniasis, J. Infect. Dis. 162 (1990) 1354-1359.
6. Assreuy J., Cunha F.Q., Epperlein M., Nohonra-Dutra A., O'Donnel C.A., Liew F.Y., Moncada S., Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major, Eur. J. Immunol. 24 (1994) 672-676.
7. Badaro R., Carvalho E.M., Rocha H., Queiroz A.C., Jones T.C., Leishmania donovani: An opprtunistic microbe associated with progressive disease in three immunocompromised patients, Lancet 1 (1986) 647-649.
8. Badaro R., Jones T.C., Lorenco R. et al., A prospective study of visceral leishmaniasis in an endemic area of Brazil, J. Infect. Dis. 154 (1986) 639-649.
9. Badaro R., Jones T.C., Carvalho E.M. et al., New perspectives on a subclinical form of visceral leishmaniasis, J. Infect. Dis. 154 (1986) 1003-1011.
10. Banchereau J., Steinman R.M., Dendritic cells and the control of immunity, Nature 392 (1998) 245-252.
11. Barral A., Pedral-Sampaio D., Grimaldi Junior G. et al., Leishmaniasis in Bahia, Brazil: Evidence that Leishmania amazonensis produces a wide spectrum of clinical disease, Am. J. Trop. Med. Hyg. 44 (1991) 536-546.
12. Barral-Netto M., Barral A., Brownell C.E., Skeiky Y.A.W., Ellingsworth L.R., Twardzik D.R., Reed S.G., Transforming growth factor-b in leishmanial infection : A parasite escape mechanism, Science 257 (1992) 545-548.
13. Beebe A., Mauze S., Schork N.J., Coffman R.L., Serial backcross mapping of multiple loci associated with the resistance to Leishmania major in mice, Immunity 6 (1997) 551-557.
14. Ben Ismaïl R., Ben Rachid M.S., Épidémiologie des leishmanioses en Tunisie. Aupelf-Uref, ed. Maladies Tropicales Transmissibles, Libbey Eurotext, Paris, 1989, pp. 73-80.
15. Blackwell J.M., Genetics of host resistance and susceptibility to intramacrophages pathogens: A study of multicase families of tuberculosis, leprosy and leishmaniasis in north-eastern-Brazil, Int. J. Brazil 28 (1998) 21-28.
16. Bogdan C., Nathan C., Modulation of macrophage function by transforming growth factor-β, interleukin 4 and interleukin 10, Ann. NY. Acad. Sci. 685 (1993) 713-739.
17. Boden G., Chen X., Mozzoli M., Ryan I., Effect of fasting on serum leptin in normal human subjects, J. Clin. Endocrinol. Metab. 81 (1996) 3419-3423.
18. Bretscher P.A., Wei G., Menon J.N., Bielefeldt-Ohmann H., Establishment of stable, cell-mediated immunity that makes susceptible mice resistant to Leishmania major, Science 257 (1992) 539-542.
19. Brittingham A., Morrison C.J., Mc Master W.R., Mc Gwire R.S., Chang K-P., Mosser D.M., Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion and resistance to complement-mediated lysis, J. Immunol. 155 (1995) 3102-3111.
20. Brown J.A., Titus R.G., Nabavi N., Glimcher L.H., Blockade of CD86 ameliorates Leishmania major infection by down regulating the Th2 response, J. Infec. Dis. 147 (1996) 1303-1308.
21. Cacares-Dittmar G., Tapia F.J., Sanchez M.A., et al., Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction, Clin. Exp. Immunol. 91 (1993) 500-505.
22. Cambell K.A., Ovendale P.J., Kennedy M.K., Fanslow W.C., Reed S.G., Maliszewski C.R., CD40 ligand is required for protective cell-mediated immunity to Leishmania major, Immunity 4 (1996) 283-289.
23. Carrera L., Gazzinelli R.T., Badolato R., Hieny S., Müller W., Kühn R., Sacks D.L., Leishmania promastigotes inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice, J. Exp. Med. 183 (1996) 515-526.
24. Carvalho E.M., Teixeira R., Johnson W.D., Cell mediated immunity in American visceral leishmaniasis: Reversible immunosuppresion during acute infection, Infect. Immun. 33 (1981) 498-500.
25. Carvalho E.M., Badaro R., Reed S.G., Jones T.C., Johnson W.D.Jr., Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis, J. Clin. Invest. 76 (1985) 2066-2069.
26. Carvalho E.M., Johnson W.D., Barreto E. et al., Cell mediated immunity in American cutaneous and mucosal leishmaniasis, J. Immunol. 135 (1985) 4144-4148.
27. Carvalho E.M., Barral A., Pedral-Sampaio D., Barral-Netto M. et al., Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi, J. Infect. Dis. 165 (1992) 535-540.
28. Cascio A., Gradoni L., Scarlata F. et al., Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy. Am. J. Trop. Med. Hyg. 57 (1997) 75-78.
29. Caserta M.T., Hall C.B., Schnabel K., Long C.E., D'Heron N., Primary human herpesvirus 7 infection: A comparison of human herpesvirus 7 and herpesvirus 6 infections in children, J. Peditr. 133 (1998) 386-389.
30. Cason J., Ainley C.C., Wolstencroft R.A., Norton K.R., Thomson R.P., Cell-mediated immunity in anorexia nervosa, Clin. Exp. Immunol. 64 (1986) 370-375.
31. Castes M., Agnelli A., Verde O., Rondon A.J., Characterization of the cellular immune response in American cutaneous leishmaniasis, Clin. Immunol. Immunopath. 27 (1983) 176-186.
32. Chandra R.K., Nutrition and immunity: Lessons from the past and new insights into the future, Am. J. Clin. Nutr. 53 (1991) 1087-1101.
33. Cillari E., Vitale G., Arcoleo F. et al., In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis, Cytokine 7 (1995) 740-745.
34. Clauvel J.P., Couderc L.J., Belmin J., Daniel M.T., Rabian C., Seligmann M., Visceral leishmaniasis complicating acqired immuno-deficiency syndrome (AIDS), Trans. R. Soc. Trop. Med. Hyg. 80 (1986) 1010-1011.
35. Comité OMS d'experts., Lutte contre les leishmanioses, série des rapports techniques OMS, Genève. 793 (1990) 177 pp.
36. Conceicao-Silva F., Hahne M., Schroter M., Louis J., Tshopp J., The resolution of lesion induced by Leishmania major in mice requires functional Fas (APO-1, CD95) pathway of cytotoxicity, Eur. J. Immunol. 28 (1998) 237-245.
37. Constant S.L., Bottomly K., Induction of the Th1 and Th2 CD4+ T cell responses: An alternative approach, Ann. Rev. Immunol. 15 (1997) 297-322.
38. Culley F.J., Harris R.A., Kaye P.M., McAdam K.P.W.J., Raynes J.G., C-reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages, J. Immunol. 156 (1996) 4691-4696.
39. Darnell J.E., Kerr I.M., Stark G.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins, Science 264 (1994) 1415-1421.
40. da Silva R., Hall B.F., Joiner K.A., Sacks D.L., CR1, the C3b receptor, mediates binding of infective metacyclic promastigotes to human macrophages, J. Immunol. 143 (1989) 617-622.
41. Dellagi K., Kbaier C., Louzir H., Guizani I., Ben Salah A., Ben Ismail R., Experimental leishmaniasis in BALB/c mice as a model to study virulence of Leishmania major strains isolated from patients with cutaneous leishmaniasis, Am. J. Trop. Med. Hyg. 55 (1996) 213 (abstract).
42. de Medieros I.M., Castelo A., Salomao R., Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis, Rev. Inst. Med. Trop. Sao. Paulo. 40 (1998) 31-34.
43. de Waal-Malefyt R., Haanen J., Spits H. et al., IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen presenting capacity of monocytes via down-regulation of class II MHC expression, J. Exp. Med. 174 (1991) 915-924.
44. D'Oliveira Jr. A., Costa S.R., Barbosa A.B., Orge M.G., Carvalho E.M., Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis, Mem. Inst. Oswaldo Cruz 21 (1997) 15-20.
45. Dyson P.J., Knight A.M., Fairchild S. et al., Genes encoding ligands for deletion of Vb11 T cells cosegregate with mammary tumor virus genomes, Nature 349 (1991) 531-532.
46. El Hassen A.M., Ghalib H.W., Zijlstra E.E., Post kala-azardermal leishmaniasis in the Sudan: Clinical features, pathology and treatment, Trans. R. Soc. Trop. Med. Hyg. 86 (1992) 245-248.
47. Eltoum I.A., Zijlstra E.E., Ali M.S. et al., Congenital kala-azar and leishmaniasis in the placenta. Am. J. Trop. Med. Hyg. 46 (1992) 57-62.
48. Etges R., Muller I., Progressive disease or protective immunity to Leishmania major infection: The results of a network of stimulatory and inhibitory reactions, J. Mol. Med. 76 (1998) 372-390.
49. Faghiri Z., Tabei S.Z., Taheri F., Study of the association of HLA class I antigens with kala-azar, Hum. Hered. 45 (1995) 258-261.
50. Farrel J.P., Muller I., Louis J.A., A role for Lyt-2+ T cells in resistance to cutaneous leishmaniasis in immunized mice, J. Immunol. 142 (1989) 2052-2056.
51. Fernandez-Guerreiro M.L., Aguado J.M., Buzon L. et al., Visceral leishmaniasis in immunocompromised hosts, Am. J. Med. 83 (1987) 1098-1102.
52. Galib H.W., Piuvezam M.R., Skeiky Y.A.M. et al., Interleukin-10 production correlates with pathology in human Leishmania donovani infection, J. Clin. Invest. 92 (1993) 324-329.
53. Galvao-Castro B., Sa Ferreira J.A., Marzochi K.F., Marzochi M.C., Coutinho S.G., Lambert P.H., Polyclonal B cell activation, circulating immune complexes and autoimmunity in human American visceral leishmaniasis, Clin. Exp. Immunol. 56 (1984) 58-66.
54. Gasim S., Elhassen A.M., Khalil E.A. et al., High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post kalaazar dermal leishmaniasis, Clin. Exp. Immunol. 111 (1998) 64-69.
55. Gazzinelli R.T., Hieny S., Wynn T.A., Wolf S., Sher A., Interleukin 12 is required for the T-lymphocyte-independent induction of interferon γ by an intracellular parasite and induces resistance in T-cell deficient hosts, Prc. Natl. Acad. Sci. USA 90 (1993) 6115-6119.
56. Gramiccia M., Gradoni L., Troiani M., Hiv-Leishmania co-infection in Italy. Isoenzyme characterization of Leishmania causing visceral leishmaniasis in Hiv patients, Trans. R. Soc. Trop. Med. Hyg. 86 (1992) 161-163.
57. Green S.J., Meltzer M.S., Hibbs J.B., Nacy C.A., Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine dependent killing mechanism, J. Immunol. 144 (1990) 278-286.
58. Griffin D.E., Ward B.J., Differential CD4 T cell activation in measles, J. Infect. Dis. 168 (1993) 275-281.
59. Grimaldi G. Jr., Tesh R.B., McMahon-Pratt D., A review of the geographic distribution and epidemiology of leishmaniasis in the new world, Am. J. Trop. Med. Hyg. 41 (1989) 687-725.
60. Gutierrez-Macias A., Alonso-Alonso J.J., Aguirre-Errasti C., Πsophageal leishmaniasis in a patient infected with the human immunodeficiency virus, Clin. Infect. Dis. 21 (1995) 229-230.
61. Guy R.A., Melosevic M., Comparison of receptors required for entry of Leishmania major amastigotes into macrophages, Infect. Immun. 61 (1993) 1553-1558.
62. Hall L.R., Titus R.G., Sandfly vector saliva selectively modulates macrophage functions that inhibit killing of Leishmania major and nitric oxide production, J. Immunol. 155 (1995) 3501-3506.
63. Harrat Z., Pratlong F., Bellazoug S., et al., Leishmania infantum and L. major in Algeria, Trans. R. Soc. Trop. Med. Hyg. 90 (1996) 625-629.
64. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M., Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for the expansion of distinct helper T cell subsets, J. Exp. Med. 169 (1989) 59-72.
65. Hill J.O., Awwad M., North R.J., Elimination of CD4+ suppressor T cells from susceptible BALB/c mice release CD8+ T lymphocytes to mediate protective immunity against Leishmania, J. Exp. Med, 169 (1989) 1819-1827.
66. Ho M., Koech D.K., Iha D.W., Bryceson A. D. M., Immunosuppression in Kenyan visceral leishmaniasis, Clin. Exp. Immunol. 51 (1983), 207-214.
67. Hsieh C.-S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., Murphy K.M., Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages, Science 260 (1993) 547-549.
68. Hsu D-H., de Waal-Malefyt R., Fiorentino D.F. et al., Expression of IL-10 activity by Epstein-Barr virus protein BCRF1, Science 250 (1990) 830-832.
69. Huber M., Timms E., Mak T.W., Rollinghoff M., Lohoff M., Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice, Infect. Immun. 66 (1998) 3968-3970.
70. Isegawa Y., Ping Z., Nakano K., Sugimoto N., Yamanishi K., Human herpesvirus 6 open reading frame U12 encodes a functional beta-chemokine receptor, J. Virol. 72 (1998) 6104-6112.
71. Jaffe C.L., Argov S., Zalis M., Rachamin N., Krup M., Shoenfeld Y., Antigens recognized by sera from patients with visceral leishmaniasis, in : Hart D.T., (éd.) Leishmaniasis. The current status and new strategies for control, Plenum Press, New York, 163, 1989, pp. 295-307.
72. Julia V., Rassoulzadegan M., Glaichenhaus N., Resistance to Leishmania major induced by tolerance to a single antigen, Science 274 (1996) 421-423.
73. Jumaian N., Kamhawi S.A., Halalsheh M., Abdel-Hafez S.K., Short report: Outbreak of cutaneous leishmaniasis in nonimmune population of soldiers in Wadi Araba, Jordan, Am. J. Trop. Med. Hyg. 58 (1998) 160-162.
74. Kamanaka M., Yu P., Yoshida K. et al., Protective role of CD40 in Leishmania major infection at two distinct phase of cell-mediated immunity, Immunity 4 (1996) 275-281.
75. Karp C.L., El-Safi S.H., Wynn T.A. et al., In vivo cytokine profiles in patients with Kala-azar. Marked elevation of both interleukin-10 and interferongamma, J. Clin. Invest. 91 (1993) 1644-1648.
76. Karp C.L., Wysocka M., Wahl L.M. et al., Mechanism of suppression of cell-mediated immunity by measles virus, Science 273 (1996) 228-231.
77. Kemp M., Hey A.S., Kurtzhals J.A.L. et al., Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis, Clin. Exp. Immunol. 96 (1994) 410-415.
78. Kenney R. T., Sacks D. L. Gam A. A., Murray H. W., Sundar S., Splenic cytokine response in Indian kala-azar before and after treatment, J. Infect. Dis. 177 (1998) 815-818.
79. Kovarik J., Siegrist C.A., Immunity in early life, Immunol. Today 19 (1998) 150-152.
80. Kubba R., Al-Gindan Y., El Hassen A.M., Omer A.H., Kutty M., Saeed M.B., Dissemination in cutaneous leishmaniasis. II. Satellite papules and subcutaneous induration, Int. J. Dermatol. 27 (1988) 702-706.
81. Laguna F., Garcia-Samaniego J., Soriano V. et al., Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: Report of five cases and review, Clin. Infect. Dis. 19 (1994) 48-53.
82. Launois P., Ohteki T., Swihart K., Mac-Donald H.R., Louis J.A., In susceptible mice, Leishmania major induces very rapid interleukin 4 production by CD4+ T cells which are NK1.1-, Eur. J. Immunol. 25 (1995) 3298-3307.
83. Launois P., Maillard I., Pingel S. et al., IL-4 rapidly produced by Vb4 Vba8 CD4+ T cells in BALB/c mice infected with Leishmania major instructs Th2 cell development and susceptibility to infection, Immunity 6 (1997) 541-549.
84. Launois P., Conceicao-Silva F., Himmerlich H., Parra-Lopez C., Tacchini-Cottier F., Louis J.A., Setting in motion the immune mechanisms underlaying genetically determined resistance and susceptibility to infection with Leishmania major, Parasite Immunol. 20 (1998) 223-230.
85. Li J., Nolan T.J., Farrell J.P., Leishmania major: A clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone, Exp. Parasitol. 87 (1997) 47-57.
86. Lord G.M., Matarese G., Howard J.K., Baker R.J., Bloom S.R., Lechler R.I., Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression, Nature 394 (1998) 897-901.
87. Louis J., Himmelrich H., Parra-Lopez C., Tacchini-Cottier F., Launois P., Regulation of protective immunity against Leishmania major in mice, Curr. Opin. Immunol. 10 (1998) 459-464.
88. Louzir H., Triki H., Bennani S. et al., Risk factors for visceral leishmaniasis : Role of Epstein-Barr virus infection, Arch. Inst. Pasteur Tunis 70 (1993) 357-362.
89. Louzir H., Belal-Kacemi L., Sassi A. et al., Natural autoantibodies, IgG antibodies to tetanus toxoid and CD5+ B cells in patients with mediterranean visceral leishmaniasis, Clin. Exp. Immunol. 95 (1994) 479-484.
90. Louzir H., Melby P.C., Ben Salah A. et al., Immunological determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major, J. Infect. Dis. 177 (1998) 1687-1695.
91. Magill A.J., Grögl M., Gasser R.A., Wellington S., Oster C.N., Visceral infection caused by Leishmania tropica in veterans of operation desert storm, N. Engl. J. Med. 328 (1993) 1383-1387.
92. Manson-Bahr P.E.C., Diagnosis, in : Peters W. & Killick-Kendrick R. (éd.), The leishmaniasis in Biology and Medicine, Academic Press, Londres, 1987, pp. 703-29.
93. Marty P., Lacour J.P., Pratlong F., Perrin C., del Giudice P., Le Fichoux Y, Leishmaniose cutanée localisée due à Leishmania infantum MON-1 contractée dans le nord de l'Algérie, Bull. Soc. Pathol. Ex. 91 (1998) 146-147.
94. Melby P.C., Andrade-Narvaez F.J., Darnell B.J., Valencia-Pacheco G., Tryon V.V., Palomo-Cetina A., Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis, Infect. Immun. 62 (1994) 837-842.
95. Meller-Melloul C., Farmarier C., Dunan S. et al., Evidences of subjects senzitized to Leishmania infantum on the French Mediterranean cost: Differences in gamma interferon production between this population and visceral leishmaniasis patients, Parasite Immunol. 13 (1991) 531-536.
96. Montalban C., Martinez-Fernandez R., Calleja J.L. et al., Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain, Rev. Infect. Dis. 11 (1989) 655-660.
97. Moore K.W., Vieira P., Fiorentino D.F., Troustine M.L., Khan T.A., Mosmann T.R., Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1, Science 248 (1990) 1230-1234.
98. Mosser D.M., Edelson P.J., The third component of complement (C3) is responsible for the intracellular survival of Leishmania major, Nature. 327 (1987) 329-331.
99. Mosser D.M., Rosenthal L.A., Leishmania-macrophage interaction: Multiple receptors, multiple ligands, and diverse cellular responses, Semin. Cell. Biol. 4 (1993) 315-325.
100. Mougneau E., Altare F., Wakil A.E. et al., Expression cloning of a protective Leishmania antigen, Science 268 (1995) 563-566.
101. Muller I., Pedrazzini T., Kropf P., Louis J., Milon G., Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells, Int. Immunol. 3 (1991) 587-597.
102. Nandan D., Reiner N.E., Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: Selective inhibition of signaling through Janus kinases and Stat1, Infect. Immun. 63 (1995) 4495-4500.
103. Neal R.A., Reeves A., Peters W., Leishmania infecting man and wild animals in Saudi Arabia. 7. Partial protection of mice against Leishmania major by prior infection with L. arabica., Trans. R. Soc. Trop. Med. Hyg. 84 (1990) 233-238.
104. Nicolle C., Statistiques des trente premières observations tunisiennes de kalaazar, Arch. Inst. Pasteur Tunis 5 (1912) 65-69.
105. Nonoyama S., Penix L.A., Edwards C.P. et al., Diminished expression of CD40 ligand by activated neonatal T cells, J. Clin. Invest. 95 (1995) 66-75.
106. O'Garra A., Cytokines induce the development of functionally heterogeneous T helper subsets, Immunity 8 (1998) 275-283.
107. Pampiglione S., Manson-Bahr P.E.C., Giungi F., Gunti G., Parenti A., Canestri-Trotti G., Studies on Mediterranean leishmaniasis. 2. Asymptomatic cases of visceral leishmaniasis, Trans. R. Soc. Trop. Med. Hyg. 68 (1974) 447-453.
108. Peters W., Elbihari S., Evans D.A., Leishmania infecting man and wild animals in Saudi Arabia. 2. Leishmania arabica n. sp., Trans. R. Soc. Trop. Med. Hyg. 80 (1986) 497-502.
109. Peters W., Bryceson A., Evans D.A., Leishmania infecting man and wild animals in Saudi Arabia. 8. The influence of prior infection with Leishmania arabica on challenge with L. major in man., Trans. R. Soc. Trop. Med. Hyg. 84 (1990) 681-689.
110. Petersen E.A., Neva F.A., Oster C.N., Bogaert Diaz H., Specific inhibition of lymphocyte-proliferation responses by adherent suppressor cells in diffuse cutaneous leishmeniasis, N. Engl. J. Med. 306 (1982) 277-285.
111. Pirmez C., Yamamura M., Uyemura K., Paes-Oliveira M., Conceicao-Silva F., Modlin R.L., Cytokine patterns in the pathogenesis of human leishmaniasis, J. Clin. Invest. 91 (1993) 1390-1395.
112. Polack E., Nahmod V.E., Emeric-Sauval E. et al., Low lymphocyte interferon-gamma production and variable proliferative response in anorexia nervosa patients, J. Clin. Immunol., 13 (1993) 445-451.
113. Puentes S.M., da Silva R.P., Sacks D.L., Hammer C.H., Joiner K.A., Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9, J. Immunol. 145 (1990) 4311-4316.
114. Roberts L.J., Badwin T.M., Curtis J.M., Handman E., Foote S.J., Resistance to Leishmania major is linked to the H2 region on chromosome 17 and chromosome 9, J. Exp. Med. 185 (1997) 1705-1710.
115. Rosenthal L.A., Sutterwala F.S., Kehrli M.E., Mosser D.M., Leishmania major-human macrophage interaction: Cooperation between Mac-1 (CD11b/CD18) and complement receptor type 1 (CD35) in promastigote adhesion, Infect. Immun. 64 (1996) 2206-2215.
116. Rosenthal P.J., Chaisson R.E., Hadley W.K., Leech J.H., Rectal leishmaniais in a patient with acquired immunodeficiency syndrome, Am. J. Med. 84 (1988) 307-309.
117. Sacks D.L., Lata L.S., Shrivastava S.N., Blackwell J., Neva F.A., An analysis of T cells responsiveness in Indian kala-azar, J. Immunol. 138 (1987) 908-913.
118. Sacks D.L., Pimenta P.F.P., Mc Conville M.J., Schneider P., Turco S.J., Stage-specific binding of Leishmania donovani to the sand fly vector midgut is regulated by conformational changes in the abundant surface lipophosphoglycan, J. Exp. Med. 181 (1995) 685-697.
119. Sassi A., Louzir H., Ben Salah A., Mokni M., Ben Osman A., Dellagi K., Leishmanin skin test lymphoproliferative response and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia, Clin. Exp. Immunol. 116 (1999) 127-132.
120. Seaman J., Mercer A.J., Sondorp H.E., Herwaldt B.L., Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited ressources, Ann. Inter. Med. 124 (1996) 664-672.
121. Singh N., Sundar S., Williams F. et al., Molecular typing of HLA class I and HLA class II in Indian kala-azar patients, Trop. Med. Int. Health 2 (1997) 468-471.
122. Soong L., Xu J.-C, Grewa L.I.S. et al., Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection, Immunity 4 (1996) 263-273.
123. Steinman R.M., Pack M., Inaba K., Dentritic cells in the T cell areas of lymphoid organs, Immunol. Rev. 156 (1997) 25-37.
124. Stenger S., Donhauser N., Thürin H., Röllinghoff M., Bogdan C., Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase, J. Exp. Med. 183 (1996) 1501-1514.
125. Sumaya C.V., Primary Epstein-Barr virus infection in children, Pediatrics 59 (1977) 16-21.
126. Sundar S., Reed S.G., Sharma S., Mehrotra A., Murray H.W., Circulating T helper 1 (Th1) cell - And Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis, Am. J. Trop. Med. Hyg. 56 (1997) 522-525.
127. Szabo S.J., Dighe A.S., Gübler U., Murphy K.M., Regulation of the interleukin (IL)-12R b2 subunit expression in developing T helper (Th) 1 and Th2 cells, J. Exp. Med. 185 (1997) 817-824.
128. Tamashiro V.G., Perez H.H., Griffin D.E., Prospective study of the magnitude and duration of changes in tuberculin reactivity during complicated and uncomplicated measles, Pediatr. Infect. Dis. J. 6 (1987) 451-454.
129. Tapia F.J., Caceres-Dittmar G., Sanchez M.A., Inadequate epidermal homing leads to tissue damage in human cutaneous leishmaniasis, Immunol. Today 15 (1994) 160-165.
130. Thakur C.P., Sinha G.P., Paudey A.K., Barat D., Sinha P.K., Amphotericin B in resistant kala-azar in Bihar, Natl. Med. J. India. 6 (1993) 57-60.
131. Trinchieri G., Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity, Ann. Rev. Immunol. 13 (1995) 251-276.
132. Vouldoukis I., Riveros-Moreno V., Dugas B. et al., The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen, Proc. Natl. Acad. Sci. USA 92 (1995) 7804-7808.
133. Vouldoukis I., Becherel P.A., Riveros-Moreno V. et al., Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation, Eur. J. Immunol. 27 (1997) 860-865.
134. Wang P.S., Evans A.S., Prevalence of antibodies to Epstein-Barr virus and cytomegalovirus in sera from a group of children in the People's Republic of China, J. Infect. Dis. 153 (1986) 150-152.
135. Wang Z.-E., Reiner S.L., Heinzel F.P., Bouvier J., Turck C.W., Locksley R.M., Targeted activation of CD8+ cells and infection of β2-microglobulin deficient mice fail to confirm a primary protective role for CD8+ cells in experimental leishmaniasis, J. Immunol. 151 (1993) 2077-2086.
136. Weigle K.A., Valderama L., Arias A.L. et al., Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction, and sensitization, Am. J. Trop. Med. Hyg. 44 (1991) 260-271.
137. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M., Positional cloning of the mouse obese gene and its human homologue, Nature 372 (1994) 425-432.